Clinical Trial

Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Dysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia. Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit. This trial will test the hypothesis that combining HD-tDCS with iTBS yields additive efficacy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-26.
Trial Details
NCT Number NCT07680959
Lead Sponsor Tri-Service General Hospital (TSGH)
Collaborators: National Science and Technology Council, Taiwan
Conditions Negative Symptoms in Schizophrenia, Brain Stimulation Intervention
Enrollment 100 participants
Start Date 2024-05-06
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09